Novel Liver-Targeting Drug Offers Hope for AAT Deficiency

The investigational drug fazirsiran improved important liver parameters associated with alpha-1-antitrypsin deficiency.
Medscape Medical News

source https://www.medscape.com/viewarticle/976287?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost